Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Furst

Showing results (491-500 of 755) with videos related to

Pageof 76
Sort By:
Expert Opinion on Drug Safety|October 21, 2011
Comparative risks of non-prescription analgesics: a structured topic review and research prioritiesEric J Lavonas, James F Fries, Daniel E Furst, et al.
ACR Open Rheumatology|March 11, 2025
Comparative Efficacy of Immunosuppressive Therapies in the Treatment of Diffuse Cutaneous Systemic SclerosisBarbara White, Daniel E Furst, Tracy M Frech, et al.
The Lancet. Rheumatology|January 12, 2026
Isolated muscular tuberculosis with secondary haemophagocytic lymphohistiocytosisWeijin Zhang, Guangzhou Du, Shaoyu Zheng, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|November 9, 2020
ReplyRobert Spiera, Lorinda Chung, Tracy Frech, et al.
Biochemistry and Biophysics Reports|May 25, 2026
Integrated single-cell transcriptomic analysis identifies <i>PF4</i> <sup><i>+</i></sup> <i>/PPBP</i> <sup><i>+</i></sup> megakaryocyte-like granulocytes associated with immune dysregulation in autoimmune diseasesShaoqi Chen, Yu Fan, Miaotong Su, et al.
Rheumatology (Oxford, England)|October 5, 2010
Gender and ethnicity differences in patients with diffuse systemic sclerosis--analysis from three large randomized clinical trialsMahsa Nashid, Puja P Khanna, Daniel E Furst, et al.
Arthritis Research & Therapy|January 1, 2017
Changes in plasma CXCL4 levels are associated with improvements in lung function in patients receiving immunosuppressive therapy for systemic sclerosis-related interstitial lung diseaseElizabeth R Volkmann, Donald P Tashkin, Michael D Roth, et al.
Annals of the Rheumatic Diseases|February 12, 2016
Sustained improvements in MRI outcomes with abatacept following the withdrawal of all treatments in patients with early, progressive rheumatoid arthritisCharles Peterfy, Gerd R Burmester, Vivian P Bykerk, et al.
American Journal of Respiratory and Critical Care Medicine|November 4, 2017
Reliability and minimal clinically important differences of forced vital capacity: Results from the Scleroderma Lung Studies (SLS-I and SLS-II)Suzanne Kafaja, Philip J Clements, Holly Wilhalme, et al.
Arthritis Research & Therapy|December 26, 2015
Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis-associated interstitial lung disease trialsDinesh Khanna, Vivek Nagaraja, Chi-Hong Tseng, et al.
Pageof 76

Showing results (491-500 of 755) with videos related to

Sort By:
Pageof 76
Expert Opinion on Drug Safety|October 21, 2011
Comparative risks of non-prescription analgesics: a structured topic review and research prioritiesEric J Lavonas, James F Fries, Daniel E Furst, et al.
ACR Open Rheumatology|March 11, 2025
Comparative Efficacy of Immunosuppressive Therapies in the Treatment of Diffuse Cutaneous Systemic SclerosisBarbara White, Daniel E Furst, Tracy M Frech, et al.
The Lancet. Rheumatology|January 12, 2026
Isolated muscular tuberculosis with secondary haemophagocytic lymphohistiocytosisWeijin Zhang, Guangzhou Du, Shaoyu Zheng, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|November 9, 2020
ReplyRobert Spiera, Lorinda Chung, Tracy Frech, et al.
Biochemistry and Biophysics Reports|May 25, 2026
Integrated single-cell transcriptomic analysis identifies <i>PF4</i> <sup><i>+</i></sup> <i>/PPBP</i> <sup><i>+</i></sup> megakaryocyte-like granulocytes associated with immune dysregulation in autoimmune diseasesShaoqi Chen, Yu Fan, Miaotong Su, et al.
Rheumatology (Oxford, England)|October 5, 2010
Gender and ethnicity differences in patients with diffuse systemic sclerosis--analysis from three large randomized clinical trialsMahsa Nashid, Puja P Khanna, Daniel E Furst, et al.
Arthritis Research & Therapy|January 1, 2017
Changes in plasma CXCL4 levels are associated with improvements in lung function in patients receiving immunosuppressive therapy for systemic sclerosis-related interstitial lung diseaseElizabeth R Volkmann, Donald P Tashkin, Michael D Roth, et al.
Annals of the Rheumatic Diseases|February 12, 2016
Sustained improvements in MRI outcomes with abatacept following the withdrawal of all treatments in patients with early, progressive rheumatoid arthritisCharles Peterfy, Gerd R Burmester, Vivian P Bykerk, et al.
American Journal of Respiratory and Critical Care Medicine|November 4, 2017
Reliability and minimal clinically important differences of forced vital capacity: Results from the Scleroderma Lung Studies (SLS-I and SLS-II)Suzanne Kafaja, Philip J Clements, Holly Wilhalme, et al.
Arthritis Research & Therapy|December 26, 2015
Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis-associated interstitial lung disease trialsDinesh Khanna, Vivek Nagaraja, Chi-Hong Tseng, et al.
Pageof 76